Navigation Links
Optimer Pharmaceuticals Announces Presentations at Upcoming IDSA Annual Meeting
Date:10/11/2010

SAN DIEGO, Oct. 11 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced two oral presentations from studies related to lead developmental product candidate, fidaxomicin, will be presented at the 48th Annual Meeting of the Infectious Disease Society of America (IDSA) to be held at the Vancouver Convention Center in Vancouver, British Columbia, Canada on October 21-24, 2010.

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)"Efficacy and Safety of Fidaxomicin vs. Vancomycin in Clostridium difficile Infection in 2 Randomized Controlled Trials with 1105 Patients"Oral Presentation: Derrick Crook, M.D.Saturday, October 23, 2010 3:30pm Pacific TimeSession: 146 Oral Abstract Session: Clostridium difficilePresentation number: 1417 "Categorization of Patients in a Large Multicenter Study of Clostridium difficile Infection Using the ATLAS Bedside Scoring System, and Correlation with Both Cure and Recurrence"Oral Presentation: Mark A. Miller, M.D.Saturday, October 23, 2010 2:00pm Pacific TimeSession: 146 Oral Abstract Session: Clostridium difficilePresentation number: 1411About Optimer PharmaceuticalsOptimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing hospital specialty products to treat serious infections and address unmet medical needs. Optimer has two anti-infective product candidates under development, fidaxomicin and Pruvel™ (prulifloxacin). Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI) and we recently initiated a rolling submission of our NDA filing to the FDA, and have filed a MAA to the EMA (Europe).  Pruvel™ is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea and we plan to have a NDA submitted to the FDA in the first quarter of 2011.
Additional information can be found at http://www.optimerpharma.com.ContactsOptimer Pharmaceuticals, Inc.Christina Donaghy, Corporate Communications ManagerJohn D. Prunty, Chief Financial Officer & VP Finance858-909-0736Canale Communications, Inc.Jason I. Spark, Senior Vice President619-849-6005
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
2. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
3. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
4. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
5. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
6. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
7. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
8. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
9. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
10. Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC
11. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... DENVER , Feb. 16, 2017 UCHealth ... hospital to utilize LungDirect for pulmonary nodule patient management. ... a nodule, or a spot on the lung, UCHealth ... spent on manual data entry. Stephanie ... been tracking my nodule patients with an Excel spreadsheet, ...
(Date:2/16/2017)... N.J. , Feb. 16, 2017  Champions Oncology, ... in the development and sale of advanced technology solutions ... oncology drugs, today announced the addition of new cohorts ... These new models will expand Champions, product line ... head and neck cancer, AML, and non-small cell lung ...
(Date:2/16/2017)... Pa. , Feb. 16, 2017  Windtree ... biotechnology company focusing on developing aerosolized KL4 surfactant ... from a preclinical influenza study showed that aerosolized ... survival in a well-established preclinical animal model. The ... a growing body of evidence that supports the ...
(Date:2/16/2017)... , Feb. 16, 2017 Paradigm Diagnostics ... B financing, adding an additional $3M from New Sciences ... Verde Venture Partners and other strategic partners at the ... further accelerating commercial adoption of their flagship Paradigm Cancer ... expanding the Paradigm cancer registry. Dr. ...
Breaking Biology Technology:
(Date:1/24/2017)... 24, 2017 Biopharm Reports has carried ... use of nuclear magnetic resonance spectroscopy (NMR). This ... profiled current practices, developments, trends and end-user plans ... growth and opportunities. These areas include growth in ... needs and innovation requirements, hyphenated NMR techniques, main ...
(Date:1/19/2017)... , January 19, 2017 According to a new report ... Forecast, 2014 - 2022," the global biometric sensor market is expected to garner ... 2022. In 2015, Asia-Pacific dominated the global market and ... sectors. Continue Reading ... ...
(Date:1/13/2017)... WASHINGTON, N.Y. , Jan. 13, 2017 /PRNewswire/ ... of technology solutions for the homecare industry, including ... of homecare industry expert, Justin Jugs, as Senior ... brings more than 15 years of homecare experience ... team in developing strategic plans to align Sandata,s ...
Breaking Biology News(10 mins):